These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The new antiarrhythmic drugs. How to put them to the best use. Anderson JL Postgrad Med; 1988 Mar; 83(4):181-93. PubMed ID: 3353335 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Woosley RL Am Heart J; 1987 Nov; 114(5):1280-91. PubMed ID: 3314444 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of moricizine in patients with congestive heart failure: a summary of the experience in the United States. Pratt CM; Podrid P; Greatrix B; Borland RM; Mahler S Am Heart J; 1990 Jan; 119(1):1-7. PubMed ID: 1688682 [TBL] [Abstract][Full Text] [Related]
10. Use of antiarrhythmic drugs in patients with heart failure: clinical efficacy, hemodynamic results, and relation to survival. Wilson JR Circulation; 1987 May; 75(5 Pt 2):IV64-73. PubMed ID: 3552304 [TBL] [Abstract][Full Text] [Related]
13. The use of antiarrhythmic agents in heart failure: implications of CAST. Gottlieb SS Am Heart J; 1989 Nov; 118(5 Pt 1):1074-7. PubMed ID: 2510486 [No Abstract] [Full Text] [Related]
14. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects. Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103 [TBL] [Abstract][Full Text] [Related]
15. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia. Packer M; Gottlieb SS; Kessler PD Am J Med; 1986 Apr; 80(4A):23-9. PubMed ID: 2871753 [TBL] [Abstract][Full Text] [Related]
16. Aggravation of arrhythmia: a complication of antiarrhythmic drugs. Podrid PJ J Cardiovasc Electrophysiol; 1993 Jun; 4(3):311-9. PubMed ID: 8269302 [TBL] [Abstract][Full Text] [Related]
18. A benefit-risk assessment of class III antiarrhythmic agents. Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126 [TBL] [Abstract][Full Text] [Related]
19. Newer antiarrhythmic drugs. Michelson EL; Dreifus LS Med Clin North Am; 1988 Mar; 72(2):275-319. PubMed ID: 3279283 [TBL] [Abstract][Full Text] [Related]
20. Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk. Podrid PJ J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S65-73. PubMed ID: 1723122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]